Perrigo Company plc (PRGO) - Full Takeover Company Value

Perrigo Corp - graphic logo of issuer PRGO

Perrigo Company plc (PRGO) maintains an impeccable image as a global expert in self-care products, which is confirmed by the market trend in share value with the 5282.08 indicator. The company dominates the pharmacy private label segment, leveraging massive production volumes to lower generic prices. The business relies on growing demand from retail chains as consumers increasingly opt for budget-friendly alternatives over expensive brand-name originals.

PRGO (perrigo.com) Total Company Value history from 11/23/2025 to 10/28/2026
Original product of Perrigo Company plc

Enterprise value combines market capitalization with net debt, determining the actual cost of a full business buyout inclusive of all liabilities. By analyzing the dynamics of the total company value, an investor can see how the regionalization of Perrigo Company plc (PRGO) raw material supply chains in the US and Europe optimizes operational risks, influencing the credit profile and the final fundamental valuation of the asset.

Competitor analysis for Perrigo Company plc

Value Adjusted for Debt and Cash Haleon PLC HLN|Enterprise Value KVUE|VRNA: Full Takeover Company Value|Total Company Value MENS|LGND (ligand.com) - Total Enterprise Value|Total Company Value Amneal AMRX|Full Business Value Alvotech S.A.|Liquidia Technologies (LQDA) - Enterprise Value|Value Adjusted for Debt and Cash Galapagos Corp (GLPG)|Enterprise Value ANIP (ANI Pharmaceuticals)|mannkindcorp.com - Enterprise Value|Total Company Value Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX: Value Adjusted for Debt and Cash|SPRY (ARS Pharma) - Total Company Value|Theravance Corp (TBPH) - Real Price to Acquire Entire Company|AQST (Aquestive Therapeutics) - Enterprise Value|Enterprise Value scPharma (SCPH)|Tectonic Therapeutic, Inc. (TECX) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash TNXP (Tonix Pharma)|SXTC: Total Company Value|EPRX - Total Enterprise Value|Real Price to Acquire Entire Company BioHarvest Sciences BHST|EXOZ - Aggregate Business Value|Enterprise Value oramed.com ORMP|Entera Bio (ENTX) - Value Adjusted for Debt and Cash|Enterprise Value HYFT (MindWalk)|Total Enterprise Value ABVC|Cumberland Pharmaceuticals (CPIX) - Total Company Value|Value Adjusted for Debt and Cash QNTM (quantumbiopharma.com)|FibroGen (FGEN) - Total Company Value|Full Business Value Telomir Pharmaceuticals Inc TELO|RANI (Rani Therapeutics Inc) - Enterprise Value|SNYR: Total Enterprise Value|Total Company Value rallybio.com RLYB|LEXX (Lexaria Bioscience Corp.) - Value Adjusted for Debt and Cash|PULM - Total Company Value|Value Adjusted for Debt and Cash Pheton|APM (Aptorum Group Limited) - Enterprise Value|Company Buyout Price Lyra Therapeutics Inc (LYRA)|IBO (Impact BioMedical) - Enterprise Value|TNF Pharmaceuticals Inc. - Full Takeover Company Value|YCBD (cbdMD Corp) - Total Company Value|PainReform Ltd (PRFX) - Total Enterprise Value|Real Price to Acquire Entire Company altamiratherapeutics.com CYTO|Lipella Pharma (LIPO) - Value Adjusted for Debt and Cash|Enterprise Value OPTN|Real Price to Acquire Entire Company PIRS|Procaps - Total Company Value|Total Enterprise Value PTPI (Petros Pharmaceuticals Inc)|Qilian International Holding Group Limited - Total Company Value|ACELYRIN Inc. - Real Price to Acquire Entire Company|Total Company Value TFF Pharmaceuticals